ema prac naion semaglutide Ozempic EMA safety committee to review

Rapid weight loss from taking GLP-1 medications like Ozempic and Wegovy can cause a decrease in muscle mass, lessen bone density, and lower your resting metabolic rate, leading to sarcopenia

PubMed Central, Konijeti, Gauree G., et al

Ozempic: A Comprehensive Comparison Both medications offer effective options for managing type 2 diabetes, allowing for personalized treatment plans

Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population

The fact that covering GLP-1s under Medicare Part D for authorized uses is already making a mark on total Part D program spending could be a sign of even higher spending to come as Part D plans are now able to cover Wegovy for its heart health benefits, and if new uses for GLP-1s are approved

Yes, and it is increasingly common in longevity-focused clinics in South Florida and nationally